ProPhase Labs, Inc. Shareholders' Equity
ProPhase Labs, Inc. (PRPH) had Shareholders' Equity of -$3.11 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-19
- 2026-06-30: Stockholders' Equity Attributable to Parent -$3.11M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$435.00K; Stockholders' Equity Attributable to Parent as first filed -$614.00K.
- 2025-12-31: Stockholders' Equity Attributable to Parent $3.51M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $6.86M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$3.11M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | -$435.00K 10-Q/A · filed 2026-07-09 | -$614.00K 10-Q · filed 2026-06-30 |
| 2025-12-31 | $3.51M 10-Q · filed 2026-08-19 | |
| 2025-09-30 | $6.86M 10-Q · filed 2025-11-19 | |
| 2025-06-30 | $11.44M 10-Q · filed 2025-11-19 | |
| 2025-03-31 | $15.12M 10-Q · filed 2025-08-13 | |
| 2024-12-31 | $7.35M 10-K · filed 2026-06-01 | |
| 2024-09-30 | $38.13M 10-Q · filed 2025-11-19 | |
| 2024-06-30 | $44.08M 10-Q · filed 2025-11-19 | |
| 2024-03-31 | $44.87M 10-Q · filed 2025-08-13 | |
| 2023-12-31 | $49.38M 10-K · filed 2026-06-01 | |
| 2023-09-30 | $56.43M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $59.26M 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $59.94M 10-Q · filed 2024-08-14 | |
| 2022-12-31 | $63.63M 10-K · filed 2025-04-01 | |
| 2022-09-30 | $67.92M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $68.16M 10-Q · filed 2023-11-13 | $68.16M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $66.44M 10-Q · filed 2023-08-11 | |
| 2021-12-31 | $58.63M 10-K · filed 2024-03-29 | |
| 2021-09-30 | $48.26M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $47.73M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $52.66M 10-Q · filed 2022-08-12 | |
| 2020-12-31 | $10.56M 10-K · filed 2023-03-29 | |
| 2020-09-30 | $10.76M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $10.89M 10-Q · filed 2021-11-12 | |
| 2020-03-31 | $10.63M 10-Q · filed 2021-08-13 | |
| 2019-12-31 | $11.23M 10-K · filed 2022-03-31 | |
| 2019-09-30 | $14.40M 10-Q · filed 2020-11-19 | |
| 2019-06-30 | $14.65M 10-Q · filed 2020-11-19 | |
| 2019-03-31 | $15.70M 10-Q · filed 2020-08-11 | |
| 2018-12-31 | $16.50M 10-K · filed 2021-03-31 | |
| 2018-09-30 | $19.70M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $20.53M 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $31.88M 10-Q · filed 2019-08-12 | $33.12M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $31.85M 10-K · filed 2020-03-26 | $33.09M 10-K · filed 2018-03-28 |
| 2017-09-30 | $35.90M 10-Q/A · filed 2018-08-20 | $36.65M 10-Q · filed 2017-11-13 |
| 2017-06-30 | $45.88M 10-Q/A · filed 2018-08-20 | $46.63M 10-Q · filed 2017-08-11 |
| 2017-03-31 | $49.92M 10-Q/A · filed 2018-08-20 | $50.67M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $5.96M 10-K · filed 2019-03-26 | |
| 2016-09-30 | $6.53M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $6.37M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $7.49M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $8.83M 10-K/A · filed 2018-08-20 | |
| 2015-09-30 | $10.04M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $8.36M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $9.37M 10-Q · filed 2015-05-13 | |
| 2014-12-31 | $10.72M 10-K/A · filed 2018-08-20 | |
| 2014-09-30 | $10.54M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $13.61M 10-Q · filed 2014-08-12 | |
| 2014-03-31 | $12.80M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $12.60M 10-K · filed 2017-02-24 | |
| 2013-09-30 | $11.63M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | $10.30M 10-Q · filed 2013-08-13 | |
| 2013-03-31 | $11.97M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $11.45M 10-K · filed 2016-03-29 | |
| 2012-09-30 | $9.89M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $8.77M 10-Q · filed 2012-08-13 | |
| 2012-03-31 | $10.63M 10-Q · filed 2012-05-11 | |
| 2011-12-31 | $11.23M 10-K · filed 2015-03-27 | |
| 2011-09-30 | $12.74M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $11.96M 10-Q · filed 2011-08-12 | |
| 2010-12-31 | $13.46M 10-K · filed 2014-03-27 | |
| 2009-12-31 | $14.06M 10-K · filed 2013-03-28 | |
| 2008-12-31 | $17.77M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |